Enanta Pharma (ENTA) Misses Q2 EPS by 11c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.09), $0.11 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $24.38 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook